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ABSTRACT
Objectives: The aim of this study was to investigate the relationship between serum vitamin D receptor (SVDR) levels and disease activity 
parameters in patients with ankylosing spondylitis (AS).
Patients and methods: Between July 2016 and January 2017, a total of 62 patients (51 males, 11 females; mean age 36.5±12.8 years; 
range, 23 to 49 years) with AS and 32 healthy volunteers (25 males, 7 females; mean age 41.57±13.6 years; range, 26 to 48 years) were included 
in the study. The SVDR levels were measured using the enzyme-linked immunosorbent assay. Erythrocyte sedimentation rate (ESR) and 
serum C-reactive protein (CRP) levels were recorded. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were used 
to assess disease activity.
Results: Although there was no significant difference between the patient and control groups (p=0.66), SVDR levels were significantly 
elevated in patients with active AS (BASDAI score ≥4) (p=0.01). The SVDR levels significantly increased in AS patients with peripheral joint 
involvement and enthesitis (p=0.01, p=0.05, respectively). The SVDR levels significantly elevated in patients treated with non-steroidal anti-
inflammatory drugs, compared to those treated with biological agents and control group (p=0.01, p=0.03, respectively). The SVDR levels 
were positively correlated with the BASDAI, CRP and ESR in the patient group (p=0.01, r=0.751; p=0.01, r=0.75; p=0.01, r=0.81, respectively).
Conclusion: Our study results suggest that serum SVDR levels are associated with the disease activity and clinical parameters in patients 
with AS. Based on these findings, SVDR level may be used as a marker of disease activity in AS.
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Ankylosing spondylitis (AS) is a chronic, systemic, 
inf lammatory disease with an unknown etiology, 
which can primarily target sacroiliac, axial and 
peripheral joints, and occasionally some organs such 
as eyes, heart, lungs, intestines, and kidneys.[1,2] In 
general, acute phase responses such as erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) 
are used in the evaluation and follow-up of the disease. 
However, these parameters do not always correlate 
with the disease activity.[1,2] Therefore, several studies 
have investigated the association of tumor necrosis 
factor-alpha (TNF-α) and a number of inflammatory 
cytokines with AS activity.[2]
Vitamin D is a hormone with immunosuppressive 
and immunoregulatory functions in addition to the 
classical effects on calcium-phosphorus metabolism. It 
acts by binding to a nuclear receptor called the vitamin 
D receptor (VDR) for activating or inhibiting the target 
genes.[3-6] Rosca and Cheung[7] reported that although 
vitamin D levels in AS patients were significantly 
lower, correction of these levels did not affect disease 
activity or function in AS patients. Although the 
proposed mechanisms have not been fully elucidated 
yet, it has been suggested that vitamin D deficiency 
and polymorphisms of VDR-encoded genes may play 
a role in the pathogenesis, disease activation, and 
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clinical features of AS.[3-7] Vitamin D regulates the 
immunological mediators, particularly via VDR. In 
addition, it has been proposed that VDR agonists 
can act as immunoreactive agents and modulators 
which may be used in the treatment of certain chronic 
inflammatory autoimmune diseases.[3-7]
It is well-known that the effect of VDR levels 
on disease activation varies according to the 
clinical condition of each individual patient.[8-10] In 
the literature, there is no study examining serum 
vitamin D receptor (SVDR) levels in patients with AS. 
In the present study, therefore, we aimed to investigate 
the relationship between SVDR levels and disease 
activity parameters in patients with AS.
PATIENTS AND METHODS
This cross-sectional study included a 
total of 62 patients (51 males, 11 females; 
mean age 36.5±12.8 years; range, 23 to 49 years) 
diagnosed with AS according to the 1984 Modified 
New York Criteria in the Ankara University Faculty of 
Medicine Immunology Department between July 2016 
and January 2017. The control group was comprised of 
a total of 32 age- and sex-matched healthy volunteers 
(25 males, 7 females; mean age 41.57±13.6 years; 
range, 26 to 48 years). Patients with acute or subacute 
viral/bacterial infections, pregnancy, cardiopulmonary 
disease, renal insufficiency, endocrine disorders such 
as hyperparathyroidism, malabsorption, recent history 
of surgical operation, systemic diseases (malignancy, 
diabetes mellitus, hypertension), prosthesis, mental 
retardation or severe emotional disturbance, smokers 
and alcohol consumers were excluded. A written 
informed consent was obtained from each participant. 
The study protocol was approved by the Clinical 
Research Ethics Committee of Ankara Yıldırım Beyazıt 
University Faculty of Medicine (13.07.2016/201). The 
study was conducted in accordance with the principles 
of the Declaration of Helsinki.
Data including demographic and clinical 
characteristics of patients and healthy controls were 
included. The presence of peripheral involvement and 
history of uveitis and enthesitis were obtained from 
the patient records. The medications of the patients 
were recorded (non-steroidal anti-inf lammatory 
drugs [NSAIDs] and biological treatment).
The SVDR level (pg/mL) was measured using 
the enzyme-linked immunosorbent assay. The ESR 
(mm/h) was measured using the Westergren tube 
method. The CRP (mg/dL) was measured using 
the nephelometric method. The Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) scores 
were calculated to evaluate the disease activity.[11] 
A BASDAI score of ≥4 indicates active AS.
 Statistical analysis
The required sample size was calculated using a 
general power analysis program (G*power; version 
3.1.9.2 software [Heinrich-Heine-Universität 
Düsseldorf, Düsseldorf, Germany]). The power of 
the study with 62 patients was calculated as 92.24% 
which was sufficient for a minimum of 80% power. 
Statistical analysis was performed using the SPSS 
version 16.0 software (SPSS Inc., Chicago, IL, USA). 
Descriptive data were expressed in mean ± standard 
deviation (SD) and median (min-max) or number 
and frequency. The Student’s t- and Mann-Whitney 
U tests were performed to assess group differences 
for continuous variables. Categorical variables were 
compared using the chi-square test. The relationship 
between two independent numerical variables was 
analyzed using the Spearman’s Rho correlation 
coefficient. A receiver operating characteristic (ROC) 
analysis was performed to determine the cut-off, 
sensitivity, and specificity values, and the calculation 
of validity and reliability analysis results for SVDR. 
A p value of <0.05 was considered statistically 
significant.
Table 1. Demographic characteristics of patient and control group
AS group (n=62) Control group (n=32)
n % Mean±SD Median Min-Max n % Mean±SD Median Min-Max
Age (year) 36.5±12.8 41.7±13.6
Sex
Male
Female
51
11
82.25
17.75
25
7
78.1
21.9
Duration of symptoms (year) 7 2-24 - -
Duration of diagnosis (year) 4 2-8 - -
AS: Ankylosing spondylitis; SD: Standard deviation; Min: Minimum; Max: Maximum.
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RESULTS
The demographic and clinical characteristics of 
the patients and controls are shown in Table 1. There 
was no significant difference in the SVDR levels 
between the AS group and control group. However, 
the SVDR levels in the patients with active AS 
(BASDAI score ≥4) significantly increased, compared 
to both of the controls and inactive AS groups (p=0.01, 
p=0.01) respectively). The ROC analysis yielded a 
value of 0.972 (p=0.01) with a lower limit of 0.894 
and upper limit of 0.997 (95% confidence interval 
[CI], 0.894-0.997). A SVDR value of >0.64 pg/mL 
had a very high sensitivity (100%) and specificity 
(95.5%) for the active patient group, and based on 
the ROC curve analysis, the most optimal cut-off 
value for active AS was 0.64 pg/mL with a negative 
predictive value of 100% and a positive predictive 
value of 97.5%. Figure 1 shows the ROC curve 
of the SVDR values for active AS patients. The 
SVDR levels significantly increased in the AS group 
with peripheral joint involvement and enthesitis 
(p=0.01, p=0.05, respectively), although there was 
no significant difference among the AS group with 
uveitis.
The SVDR levels in the AS group according to 
the BASDAI and clinical parameters are presented in 
Table 2. We also evaluated the relationship between 
the SVDR levels and treatment of AS by subgroup 
analysis. We found a significant difference in the 
SVDR levels in the patients receiving NSAID treatment 
compared to those using biological treatment 
(p=0.01). In addition, the SVDR levels of the patient 
group treated with NSAIDs were also significantly 
elevated, compared to the control group (p=0.03). 
Figure 1. Receiver operating characteristic curves of vitamin 
D receptor values in differentiating patients with active 
ankylosing spondylitis from inactive active ankylosing 
spondylitis The blue curve represents the receiver operating 
characteristic curve, and the gray line represents the diagonal 
line used as a reference.
ROC: Receiver operating characteristic.
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Table 2. Comparison of serum vitamin D receptor levels according to demographic and clinical 
parameters in ankylosing spondylitis patients
n % Median Min-Max p
SVDR levels (pg/mL)
Sex
Male
Female
51
11
82.3
17.7
- - 0.92
Involvement
Axial
Peripheral
49
13
79
21
- - 0.01**
Enthesitis
+
-
16
46
25.8
74.2
- - 0.04*
Uveitis
+
-
12
50
19.6
80.4
- - 0.20
BASDAI
<4
>4
21
41
33.9
65.1
3.04
6.56
0.24-3.80
4.78-7.12
0.01**
Min: Minimum; Max: Maximum; SVDR: Serum vitamin D receptor; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; 
(Active AS BASDAI >4); * p<0.05: Statistically significant; ** Mann Whitney U test.
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Correlation analysis revealed that the SVDR levels 
were positively correlated with the BASDAI (r=0.75, 
p=0.01), CRP (r=0.75, p=0.01), and ESR (r=0.81, 
p=0.01). However, there was no correlation between 
the SVDR levels and disease duration in patients with 
AS (r=0.094, p=0.468).
DISCUSSION
In the present study, we investigated the relationship 
between SVDR levels and disease activity parameters 
in patients with AS. According to our findings, the 
SVDR levels were found to be elevated in patients 
with active AS, compared to patients with inactive AS. 
The SVDR levels were positively correlated with the 
BASDAI scores and systemic inf lammatory markers 
such as CRP and ESR. In addition, we found a cut-off 
value for active disease with a very high sensitivity 
and specificity. These findings indicate that the SVDR 
level may be accepted as a new inflammatory marker 
and acute phase reactant to indicate clinical activity 
for AS. To the best of our knowledge, the present study 
is the first to evaluate VDR levels in patients with AS 
in the literature.
Interleukin (IL)-22, IL-17, TNF-α, IL-6, IL-10, 
toll-like receptor-4, and IL-23 are important in AS 
clinic and disease activation which are found to be 
increased and dysregulated in AS patients. The VDR is 
effective in the regulation of expression and function 
of these mediators.[12-20] The VDR may act to regulate 
nuclear factor-kappa B (NF-kB) activation which 
increases in AS and important for the expression 
of adhesion molecules and other pro-inflammatory 
genes.[21,22] It is also effective on the regulation of 
functions B cells, CD4, and CD8 T lymphocytes which 
play a critical role in AS clinic and disease activation, 
as well as reducing the activity of Wnt/β-catenin 
signaling pathway, which has important implications 
in cell adhesion and regulation of the functions in B, 
CD4, and CD8 T lymphocytes.[12,21-26] In experimental 
studies on mice, stimulation of the ß-catenin signal was 
shown to activate the Wnt pathway, leading to aberrant 
chondrocyte maturation and joint ankyloses.[27] It was 
also reported that VDR might induce apoptosis.[28,29] 
The induced chondrocyte apoptosis in AS was thought 
to play a role in the changes in bone and cartilage.[30] 
Enthesopathy, according to some authors, is considered 
a completely pathological process; however, it is a 
repair mechanism for others, indeed.[31] Pathogenesis 
of AS is still not clear. According to the literature, 
autoimmune diseases may associate with microbiota 
which plays a role in the pathogenesis by leading 
to dysfunction of VDR, due to increased release of 
antimicrobial peptides, and that the use of antibiotics 
may result in an increased VDR activation, thereby, 
leading to an increased immunological response.[32] 
In our study, the SVDR levels significantly increased 
in the AS group with peripheral joint involvement 
and enthesitis. However, further studies are needed 
to elucidate the immunomodulatory effect of SVDR 
in AS.
In the present study, the SVDR levels were also 
found to be elevated in patients receiving NSAIDs. 
Although SVDR levels in the AS patients were not 
significantly different from the controls, the BASDAI 
scores and the SVDR levels in the patients treated with 
NSAIDs significantly increased, compared to those 
using biological agents and control groups. These 
results may be associated with decreased SVDR levels 
due to suppression of disease activity with anti-TNF 
drugs. According to our results, SVDR may have a 
role as an inflammatory marker and, therefore, it may 
be suppressed by biological agents naturally. It was 
previously reported that VDR caused a significant 
decrease in the TNF-α levels in mast cells.[10] Ziv et 
al.[10] found that exposure of keratinocytes to TNF-α 
caused a significant increase in VDR levels. Pojednic 
et al.[33] also reported that VDR levels were correlated 
with IL-6 gene expression and VDR activation could 
regulate intracellular inflammation. Thus, it can be 
assumed that SVDR plays a role in decreasing disease 
activity in AS, although further researches are needed 
to shed light into this subject.
The main limitations of the present study include 
the lack of vitamin D analysis and VDR gene 
polymorphism in the patients with AS.
In conclusion, we found elevated SVDR levels in 
patients with activated AS in our study. Based on 
these results, increased SVDR levels may be associated 
with peripheral joint involvement and the presence 
of enthesitis and it may be related to disease activity 
parameters in patients with AS.
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